Prevalence of Phonophobia and Cutaneous Allodynia in Episodic Migraineurs

August 4, 2014 updated by: Thomas Jefferson University
Cutaneous allodynia is an increased skin sensitivity experienced during a headache. It has been noted in several studies that in patients with migraine, seventy nine percent of the patients experienced allodynia on the facial skin on the same side as the headache. Understanding more about the occurrence of phonophobia (increased sensitivity to sound) and allodynia may help us understand how the pain system works in migraine. It is hoped that the knowledge gained from this trial may enable us to more effectively treat patients with migraine headache.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Actual)

38

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United States
    • Pennsylvania
      • Philadelphia, Pennsylvania, United States, 19107
        • Jefferson Headache Center

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 65 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Adult women and men with a diagnosis of episodic migraine

Description

Inclusion Criteria:

Inclusion criteria for migraine subjects:

  • Age: 18 - 65 years, inclusive.
  • Gender: male or female
  • Diagnosis: Episodic migraine with or without aura, as defined by the International Headache Society (IHS), for at least 6 months prior to enrollment.
  • An average of ≥1 migraine attack per month over the 6-month period prior to enrollment.
  • An average of <15 headache (of any type) days per month for the 6 months prior to enrollment.
  • Normal audiogram. (A hearing threshold of 20 dB or less at the frequency range of 200-8000Hz.).

Inclusion criteria for control subjects:

  • Age: 18 - 65 years, inclusive.
  • Gender: male or female
  • Non-headache sufferers with the exception of infrequent ETTH according to IHS criteria (lifetime occurrence of at least 10 episodes occurring on <1 day per month on average and <12 days per year)
  • Normal audiogram, (A hearing threshold of 20 dB or less at the frequency range of 200-8000Hz.).

Exclusion criteria for migraine subjects:

  • Any other headache diagnosis (e.g. cluster headache, hemicrania continua, post traumatic headache, etc.) except for episodic tension type headache (ETTH) with an average of no more than 10 ETTH headache days per month for the 6 months prior to enrollment (note: average <15 total HA days is specified in inclusion)
  • Use of any headache preventive drug (determined by investigator) in the 90 days prior to screening.
  • Treatment with botulinum toxin (for any indication) within the 90 day period prior to enrollment.
  • Treatment with occipital nerve block or block, or block of any other nerve in the head or neck area, within the 30 day period prior to enrollment.
  • Any dermatological disease that may affect skin sensation.
  • Any neurological disease that may affect sensory functions (e.g stroke, multiple sclerosis, peripheral neuropathy).
  • Cognitive disturbance that may affect the subject's ability to understand the study procedure.
  • Significant psychiatric disturbance that may impair the subject from co-operating with the study procedures.
  • Use of acute pain medications on a daily or frequent pattern (for any indication) as defined by the IHS.

Exclusion criteria for control subjects:

  • Any other headache diagnosis except for IHS-defined infrequent ETTH.
  • Use of any headache preventive drug (determined by investigator) in the 90 days prior to screening.
  • Treatment with botulinum toxin (for any indication) within the 90 day period prior to enrollment.
  • Treatment with occipital nerve block or block, or block of any other nerve in the head or neck area, within the 30 day period prior to enrollment.
  • Any dermatological disease that may affect skin sensation.
  • Any neurological disease that may affect sensory functions (e.g stroke, multiple sclerosis, peripheral neuropathy).
  • Cognitive disturbance that may affect the subject's ability to understand the study procedure.
  • Significant psychiatric disturbance that may impair the subject from co-operating with the study procedures.
  • Use of acute pain medications on a daily or frequent pattern (for any indication) as defined by the IHS.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Subjects with episodic migraine with allodynia
These are subjects with episodic migraine with allodynia
Other: Sounds
Subjects with episodic migraine without allodynia
Other: Sounds

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Correlation Between Phonophobia (Sound Sensitivity) and Allodynia (Skin Sensitivity) in Subjects With Episodic Migraine
Time Frame: Subjects with or without allodynia return during a migraine attack and are tested for Phonophobia.
Measurement of phonophobia: determine sound aversion threshold (SAT), measured in dB during a migraine attack in subjects with and in subjects without allodynia.
Subjects with or without allodynia return during a migraine attack and are tested for Phonophobia.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Thomas Jefferson University

Investigators

  • Principal Investigator: Abraham A. Ashkenazi, M.D., Thomas Jefferson University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

August 1, 2006

Primary Completion (Actual)

August 1, 2007

Study Completion (Actual)

September 1, 2007

Study Registration Dates

First Submitted

October 11, 2006

First Submitted That Met QC Criteria

October 11, 2006

First Posted (Estimate)

October 12, 2006

Study Record Updates

Last Update Posted (Estimate)

August 22, 2014

Last Update Submitted That Met QC Criteria

August 4, 2014

Last Verified

August 1, 2014

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • AA-Phono-CA

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Migraine

Clinical Trials on Sounds

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Qatar

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe